drugset / Trial / NCT05744674

Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management

NCT05744674

Phase 2 Unknown 96 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection intercostal nerve block with HR18034 for postoperative pain management compared with ropivacaine.

Timeline

Start
2023-02-21
Primary completion
2023-06-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HR18034 Unknown 228 mg Other
Subject HR18034 Unknown 342 mg Other
Subject HR18034 Unknown 456 mg Other
Comparator Ropivacaine Other / unclassified 60 mg Other
Comparator Ropivacaine Other / unclassified 90 mg Other
Comparator Ropivacaine Other / unclassified 120 mg Other

Indications

No indication recorded.